BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /CNW/ -- SOPHiA GENETICSÂ (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on June 18, 2026, subject to customary closing conditions.
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology
